Fibrodysplasia Ossificans Progressiva Market
what is fop in business
Fibrodysplasia Ossificans Progressiva (FOP) is a disorder in which muscle tissue and connective tissue like tendons and ligaments are replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone), which constrains movement.
FOP becomes apparent early in childhood. Infants are usually born with short, malformed big toes. About half of people with the disease also have malformed thumbs. Bone overgrowth tends to commence in the neck and shoulders, causing periodic bouts of painful inflammation. A low-grade fever sometimes accompanies this.
Fibrodysplasia Ossificans Progressiva Market
The market size of Fibrodysplasia Ossificans Progressiva in 7MM in 2017 was 1.76 USD Million
What are the Fibrodysplasia Ossificans Progressiva Market Drivers?
Increase in the Research and Development Activity
Upcoming Launches and Approval
Awareness
What are the Fibrodysplasia Ossificans Progressiva Market Barriers?
Fewer Patients
Diagnosis Paradigm
High Cost of Emerging Therapies
What are the Fibrodysplasia Ossificans Progressiva Emerging Drugs?
The emerging drugs of the Fibrodysplasia Ossificans Progressiva market are
Palovarotene
Garetosmab (REGN2477)
BLU-782
INCB00928
Saracatinib (AZD0530 Difumarate)
TAK 165
And many others.
What are the Fibrodysplasia Ossificans Progressiva Key Players?
The key players in the Fibrodysplasia Ossificans Progressiva market are
Ipsen
Regeneron Pharmaceuticals
Incyte Corporation
VU University Medical Center (Collaborator: AstraZeneca)
Kyoto University (Collaborator: Takeda)
And many others.
What is C3G Treatment?
Complement 3 Glomerulopathy (C3G) is a group of rare kidneys diseases that are driven by dysregulation of the complement cascade. It is a type of glomerular disease, which is characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a major amount of immunoglobulin and without deposition of C1q and C4.
The term C3G covers the dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) that are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when seen under a microscope. People with DDD generally present at a younger age (childhood or adolescence) as compared to people with C3GN (adulthood).
The market size of C3G in 7MM in 2017 was USD 40.6 Million
What are the Complement 3 Glomerulopathy Market Drivers?
Intermediate Pipeline Activity
Increase in Awareness
The advent of Biomarkers in Near Future
What are the Complement 3 Glomerulopathy Market Barriers?
Hurdles in Clinical Trial Settings
Drawbacks of Renal Replacement Therapy
Prone to Recurrence
The Dominance of off-label Therapies
What are the Complement 3 Glomerulopathy Emerging Drugs?
The emerging drugs of the Complement 3 Glomerulopathy market are
Danicopan (ACH-4471/ALXN2040)
Narsoplimab (OMS721)
Pegcetacoplan (APL-2)
LNP023 (TBD)
And many others.
What are the Complement 3 Glomerulopathy Key Players?
The key players in the Complement 3 Glomerulopathy market are
Alexion Pharmaceuticals
Omeros Corporation
Apellis Pharmaceuticals
Novartis Pharmaceuticals
And many others.
Infographic bipolar disorder
Bipolar Disorder, formerly known as manic depressive illness or manic depression, is a mental disorder that is characterized by wide mood swings from manic to depressed. In depressive episodes (bipolar depression), the patient might feel sad, indifferent, or hopeless, combined with a shallow activity level.
The symptoms of bipolar depression are feeling sad or anxious; restless; trouble focusing or making decisions; trouble falling asleep, waking up too early, or sleeping too much; lack of interest; feeling hopeless or worthless, or thinking about death or suicide; unable to do even simple things, and talking very slowly.
The market size of Bipolar Depression in 7MM in 2017 was USD 762.83 million.
What are the Bipolar Depression Market Drivers?
Novel insights into disease
Improvement in treatment over the years
Increasing adherence to treatment
Increase in awareness and advancements in the technology
What are the Bipolar Depression Market Barriers?
Delay in diagnosis
Unrecognized and inappropriate treatment
Neglects of quality of life, burden, and economic issues
Unsatisfactory design of randomized controlled trials
Lack of Knowledge to differentiate between unipolar and bipolar depression
What is the Bipolar Depression Emerging Drugs?
The emerging drugs of the Bipolar Depression market are
Abilify (Aripiprazole)
Lumateperone/ITI-007
NRX-100/NRX-101
Psilocybin
Zuranolone (SAGE-217)
SEP-4199
ILT101
Falkieri (Esketamine DPI)
And many others.
What are the Bipolar Depression Key Players?
The key players in the Bipolar Depression market are
Otsuka Pharmaceutical
Intra-cellular Therapies
NeuroRx
COMPASS Pathways
Sage Therapeutics
Sunovion/Sumitomo Dainippon Pharma
Iltoo Pharma
Celon Pharma
And many others.
Source: - Infographic Bipolar Disorder
Comments